Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Bemfivastatin hemicalcium (PPD 10558), an orally active HMG-CoA reductase inhibitor, serves as a lipid-lowering agent. It amplifies liver extract activity and exhibits no-observed adverse effect levels (NOAEL) at dosages of ≥320 mg/kg/d for rat developmental toxicity, ≥12.5 mg/kg/d for rabbit maternal toxicity, and ≥25 mg/kg/d for rabbit developmental toxicity. This compound is utilized in research concerning hypercholesterolemic myalgia in patients intolerant to statins.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | Bemfivastatin hemicalcium (PPD 10558), an orally active HMG-CoA reductase inhibitor, serves as a lipid-lowering agent. It amplifies liver extract activity and exhibits no-observed adverse effect levels (NOAEL) at dosages of ≥320 mg/kg/d for rat developmental toxicity, ≥12.5 mg/kg/d for rabbit maternal toxicity, and ≥25 mg/kg/d for rabbit developmental toxicity. This compound is utilized in research concerning hypercholesterolemic myalgia in patients intolerant to statins. |
Synonyms | PPD 10558 hemicalcium |
Molecular Weight | 607.67 |
Formula | C34H36FN2O6.1/2Ca |
CAS No. | 805241-64-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Bemfivastatin hemicalcium 805241-64-9 PPD 10558 hemicalcium inhibitor inhibit